Treatment of Acute Optic Neuritis and Vision Complaints in Multiple Sclerosis

Current Treatment Options in Neurology

Volumn 17, Issue 1, 2015, Pages

  Torres Torres, Ruben ^a   Sanchez Dalmau, Bernardo F ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Afferent symptoms; Efferent symptoms; Multiple sclerosis; Neuro ophthalmology; Ocular symptoms; Optic neuritis; Treatment

Indexed keywords

BETA1A INTERFERON; FINGOLIMOD; GLATIRAMER; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; NATALIZUMAB; STEROID;

AFFERENT PUPILLARY DEFECT; BINOCULAR CONVERGENCE; CATARACT; CHILL; CONTACT LENS; CRANIAL NERVE PARALYSIS; DEMYELINATION; DEPRESSION; DIABETIC NEUROPATHY; DIFFERENTIAL DIAGNOSIS; DYSMETRIA; ELECTROPHYSIOLOGY; EXERCISE; EXPERIMENTAL THERAPY; EYE INFLAMMATION; EYE MOVEMENT; EYE PAIN; EYE SWELLING; FATIGUE; GLAUCOMA; HEADACHE; HUMAN; IMMEDIATE TYPE HYPERSENSITIVITY; INTERMEDIATE UVEITIS; INTERNUCLEAR OPHTHALMOPLEGIA; MACULAR EDEMA; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; NYSTAGMUS; OPTIC DISK; OPTIC NEURITIS; OPTICAL COHERENCE TOMOGRAPHY; PLASMAPHERESIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PULFRICH PHENOMENON; RASH; RETINA DISEASE; REVIEW; SACCADIC DYSMETRIA; SCOTOMA; SIDE EFFECT; SLIT LAMP; SPECTACLES; THORAX PAIN; UHTHOFF PHENOMENON; UVEITIS; VASCULAR DISEASE; VISION TEST; VISUAL FIELD DEFECT; VISUAL IMPAIRMENT;

EID: 84919935309     PISSN: 10928480     EISSN: 15343138     Source Type: Journal    
DOI: 10.1007/s11940-014-0328-z     Document Type: Review

References (43)

1. Foroozan R, Buono LM, Savino PJ, Sergott RC. Acute demyelinating optic neuritis. Curr Opin Ophthalmol. 2002;13(6):375–80.
2. Martínez-Lapiscina E, Sanchez-Dalmau B, Fraga-Pumar E, Ortiz-Perez S, Tercero-Uribe A, Torres-Torres R, et al. The visual pathway as a model to understand brain damage in multiple sclerosis. Mult Scler. 2014.
3. Optic Neuritis Study Group. The clinical profile of optic neuritis. Experience of the Optic Neuritis Treatment Trial. Arch Ophthalmol. 1991;109(12):1673.
4. de la Cruz J, Kupersmith MJ. Clinical profile of simultaneous bilateral optic neuritis in adults. Br J Ophthalmol. 2006;90(5):551.
5. Beck RW, Gal RL, Bhatti MT, Brodsky MC, Buckley EG, Chrousos GA, et al. Visual function more than 10 years after optic neuritis: experience of the optic neuritis treatment trial. Am J Ophthalmol. 2004;137(1):77–83.
6. Noseworthy JH, O'Brien PC, Petterson TM, et al. A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis. Neurology. 2001;56:1514.
7. Roed HG, Langkilde A, Sellebjerg F, et al. A double-blind, randomized trial of IV immunoglobulin treatment in acute optic neuritis. Neurology. 2005;64:804.
8. Ruprecht K, Klinker E, Dintelmann T, et al. Plasma exchange for severe optic neuritis: treatment of 10 patients. Neurology. 2004;63:1081.
9. Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet. 2001;357:1576.
10. CHAMPS Study Group. Interferon beta-1a for optic neuritis patients at high risk for multiple sclerosis. Am J Ophthalmol. 2001;132:463.
11. Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology. 2006;67:1242.
12. Comi G, Martinelli V, Rodegher M, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet. 2009;374:1503.
13. Heron G, Thompson KJ, Dutton GN. The symptomatic Pulfrich phenomenon can be successfully managed with a coloured lens in front of the good eye—a long- term follow-up study. Eye (Lond). 2007;21:1469–72.
14. McGowan G, Ahmed TY, Heron G, Diaper C. The Pulfrich phenomenon; clumsiness and collisions which can be ameliorated. Pract Neurol. 2011;11(3):173–6.
15. Perkin GD, Rose FC. Uhthoff’s syndrome. Br J Ophthalmol. 1976;60(1):60–3.
16. Davis SL, Frohman TC, Crandall CG, et al. Modelling Uhthoff’s phenomenon in MS patients with internuclear ophthalmoparesis. Neurology. 2008;70(13 pt 2):1098Y1106.
17. Rae-Grant AD. Unusual symptoms and syndromes in multiple sclerosis. CONTINUUM Lifelong Learn Neurol. 2013;19(4):992–1006. The very latest and most comprehensive review of unusual symptoms and síndromes. in MS; essential reading.
18. Keltner JL, Johnson CA, Spurr JO, et al. Baseline visual field profile of optic neuritis: the experience of the Optic Neuritis Treatment Trial. Optic Neuritis Study Group. Arch Ophthalmol. 1993;111:231–4.
19. Plant GT, Kermode AG, Turano G, et al. Symptomatic retrochiasmal lesions in multiple sclerosis: clinical features, visual evoked potentials, and magnetic resonance imaging. Neurology. 1992;42:68–76.
20. Francis CE. Visual issues in multiple sclerosis. Phys Med Rehabil Clin N Am. 2013;24(4):687–702.
21. Zee DS. Internuclear ophthalmoplegia: pathophysiology and diagnosis. Baillieres Clin Neurol. 1992;1:455–70.
22. Frohman EM, Frohman TC, O’Suilleabhain P, et al. Quantitative oculographic characterisation of internuclear ophthalmoparesis in multiple sclerosis: the versional dysconjugacy index Z score. J Neurol Neurosurg Psychiatry. 2002;73:51–5.
23. Serra A, Derwenskus J, Downey DL, et al. Role of eye movement examination and subjective visual vertical in clinical evaluation of multiple sclerosis. J Neurol. 2003;250:569–75.
24. Bolanos I, Lozano D, Cantu C. Internuclear ophthalmoplegia: causes and long-term follow-up in 65 patients. Acta Neurol Scand. 2004;110:161–5.
25. Frohman EM, Frohman TC, Zee DS, McColl R, Galetta S. The neuro-ophthalmology of multiple sclerosis. Lancet Neurol. 2005;4(2):111–21.
26. Niestroy A, Rucker JC, Leigh RJ. Neuro-ophthalmologic aspects of multiple sclerosis: using eye movements as a clinical and experimental tool. Clin Ophthalmol. 2007;I(3):267–72.
27. Graves J, Balcer LJ. Eye disorders in patients with multiple sclerosis: natural history and management. Clin Ophthalmol. 2010;4:1409–22. A full update of the visual manifestations of multiple sclerosis and its management. Recommended reading.
28. Averbuch-Heller L, Tusa RJ, Fuhry L, et al. A double-blind controlled study of gabapentin and baclofen as treatment for acquired nystagmus. Ann Neurol. 1997;41:818–25.
29. Starck M, Albrecht H, Pollman W, et al. Drug therapy for acquired pendular nystagmus in multiple sclerosis. J Neurol. 1997;244:9–16.
30. Rucker JC. Current treatment of nystagmus. Curr Treat Options Neurol. 2005;7:69–77.
31. Leigh RJ, Tomsak RL. Drug treatments for eye movement disorders. J Neurol Neurosurg Psychiatry. 2003;74:1–4.
32. Buckley EG, Holgado S. Surgical treatment of upgaze palsy in Parinaud’s syndrome. J AAPOS. 2004;8:249–53.
33. Postert T, McMonagle U, Buttner T, et al. Paroxysmal convergence spasm in multiple sclerosis. Acta Neurol Scand. 1996;94(1):35–7.
34. Renfro L, Snow JS. Ocular effects of topical and systemic steroids. Dermatol Clin. 1992;10(3):505–12.
35. Orbach H, Katz U, Sherer Y, Shoenfeld Y. Intravenous immunoglobulin. Clin Rev Allerg Immunol. 2005;29(3):173–84.
36. Oh KT, Boldt HC, Danis RP. Iatrogenic central retinal vein occlusion and hyperviscosity associated with high-dose intravenous immunoglobulin administration. Am J Ophthalmol. 1997;124(3):416–8.
37. Rubio JE, Charles S. Interferon-associated combined branch retinal artery and central retinal vein obstruction. Retina. 2003;23:546–8.
38. Tokai R, Ikeda T, Miyaura T, Sato K. Interferon-associated retinopathy and cystoid macular edema. Arch Ophthalmol. 2001;119:1077–9.
39. Cohen JA, Rovaris M, Goodman AD, et al. Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS. Neurology. 2007;68(12):939–44.
40. Comi G, Filippi M, Wolinsky JS, et al. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol. 2001;49(3):290–7.
41. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362:402–15.
42. Highlights of prescribing information: Gilenya (fingolimod) capsules. Novartis. 2012.
43. Clifford DB, DeLuca A, Simpson DM, Arendt G, Giovannoni G, Nath A. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol. 2010;9(4):438–46.